Physical Exercise Program for Adults With Diffuse Interstitial Lung Disease in a Pulmonary Rehabilitation Context
- Sponsor
- Universidad de La Frontera
- Study ID
- NCT07061873
- Status
- Enrolling By Invitation
Conditions
- Interstitial Lung Disease Due to Systemic Disease (Disorder)
- Interstitial Lung Disease in Patients With Rheumatoid Arthritis
- Pulmonary Fibrosis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Aerobic excersise — PROCEDURE20 aerobic exercise sessions, with a duration of 45 to 60 minutes, for 10 weeks.
- Muscle strength limbs, inspiratory muscle strength — PROCEDURE20 sessions of exercise Muscle strength limbs, inspiratory muscle strength, with a duration of 60 minutes, for 10 weeks
Study Details
This study aims to evaluate the effectiveness of an exercise program that includes three exercise modalities (Aerobic, Limb Strength and Respiratory Muscle Strength) versus an exercise program that includes only one modality (Aerobic) in the context of a Pulmonary Rehabilitation program in adults with diffuse interstitial disease in the Araucanía Region, in terms of exercise tolerance. A randomized clinical trial will be conducted, with 2 parallel groups, with masked evaluator. This study will include adults with a diagnosis of Diffuse Interstitial Lung Disease who are referred according to their medical condition and who agree to participate through an informed consent form. Participants will be recruited in the community and will be referred to the Physical Function and Rehabilitation Laboratory of the Faculty of Medicine of the Universidad de La Frontera, where they will be evaluated and subsequently randomly assigned to each group. The evaluation consists of a series of tests and instruments to collect information regarding dyspnea, exercise tolerance, muscle strength and lung function, among others. The intervention corresponds to a Pulmonary Rehabilitation program, where both groups will receive education in psychological and nutritional aspects, self-care and physical activity. The difference between groups is that the control group will receive an intervention with an aerobic exercise modality and the experimental group will receive three exercise modalities together (aerobic, strengthening of extremities and strengthening of respiratory muscles).The program will last 10 weeks, with sessions twice a week, and at the end of the program the initial parameters will be re-evaluated. Data analysis will be performed using descriptive statistical elements, such as distribution tables and graphs. The inferential analysis will be performed using Chi2 for the association between the intervention and the main outcome variable, in addition to the calculation of RR to assess the magnitude of the association; the secondary outcome variables will be calculated for the primary outcome variable association; secondary outcome variables will be analyzed using Student's t-test.
Key Dates
- Start date
- Oct 1, 2024
- Status verified
- Jul 2025
- Primary completion
- May 1, 2026
- Completion
- Sep 1, 2026
Study Design
- Enrollment
- 29 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Other: ControlControl (Aerobic excercise)
- Experimental: InterventionIntervention (Muscle strength limbs, inspiratory muscle strength, aerobic exercise)
Primary Outcome Measure
Exercise tolerance [ Time Frame: Baseline and then at the end of the 10-week training period ]
Related Studies
- Role of Genetic Factors in the Development of Lung DiseaseRecruiting · National Heart, Lung, and Blood Institute (NHLBI) · Bethesda, Maryland
- Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis (IPF)Recruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
- Explanted Lung Tissues With Pulmonary FibrosisRecruiting · University of Chicago · Chicago, Illinois
- Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis PatientsPHASE1 · Recruiting · Massachusetts General Hospital · Boston, Massachusetts